Huang, Weng-Foung; Tsai, Yi-Wen; Wen, Yu-Wen; Hsiao, Fei-Yuan; Kuo, Ken N.; Tsai, Chia-Rung
Menopause. 17(1):57-63, January 2010.
doi: 10.1097/gme.0b013e3181b34749
No differences were found between alendronate and raloxifene on the risk of atrial fibrillation and flutter in women with osteoporosis. However, a significant association was found between long-term use of alendronate and increased risk of acute myocardial infarction in women with a history of cardiovascular events.